Discovering significant breakthroughs in fibrosis.

Our Mission

To bring life changing and revolutionary treatments to patients with fibrotic diseases.

Blade Therapeutics is advancing innovative anti-fibrotic therapies to meet currently unserved patient needs. Several rare/orphan and chronic debilitating conditions manifest with fibrosis, a complex, pathologic process in which healthy cells are replaced by progressively worsening scar tissue (fibrosis). We are committed to developing disease modifying and lifesaving treatments.

Blade is advancing a risk-diversified product portfolio to address various fibrotic diseases and their underlying pathophysiology. The Company has assembled a critical mass of fibrosis expertise, a top-tier leadership team, and a world-class network of expert advisors. Blade’s founding programs are based on the discoveries of Hal Dietz, M.D., Victor A. McKusick Professor of Genetics and Medicine, Johns Hopkins University. His pioneering research elucidated a biological pathway that underpins our research activities at Blade. His findings are now enabling the insights and advancement of small molecules to treat and potentially reverse fibrosis.

Our Leadership

Management Team

Wendye Robbins photo

Wendye Robbins, M.D.

President & CEO

Gary Patou photo

Gary Patou, M.D.

Chief Medical Officer

Felix Karim photo

Prabha Ibrahim, Ph.D.

Chief Technology Officer

Maria Fuentes photo

Maria Fuentes, Ph.D.

Executive Vice President of Research

Felix Karim photo

Felix Karim, Ph.D.

Executive Vice President, Business Development

photo of Joanne Imperial

Joanne Imperial

Vice President of Clinical Research

photo of Scott Henley

Scott Henley

Vice President of Clinical Development

photo of Daven Mody

Daven Mody

Vice President of Regulatory Affairs

photo of H. Shirley Chiang

H. Shirley Chiang

Vice President of Finance

photo of Ravi Rajagopalan

Ravi Rajagopalan

Executive Director, Drug Discovery

Board Of Directors

Luke Evnin photo

Luke Evnin, Ph.D.

Managing Director at MPM
Chairman Of The Board For Blade

Jim Scopa photo

Jim Scopa, J.D., M.B.A.

Managing Director at MPM

Cameron Wheeler photo

Cameron Wheeler, Ph.D.

Partner at Deerfield

William Slattery photo

William Slattery

Partner at Deerfield

Rana Al-Hallaq photo

Rana Al-Hallaq, Ph.D.

Senior Director And Principal
at Pfizer Ventures

Peter Van Vlasselaer photo

Peter Van Vlasselaer, Ph.D.

Founder, CEO, And Director
of Armo Biosciences

photo of Lloyd Klickstein

Lloyd Klickstein, M.D., Ph.D.

Chief Scientific Officer
RestorBio

Wendye Robbins photo

Wendye Robbins, M.D.

President & CEO
Blade Therapeutics, Inc.

Scientific Advisors

Hal Dietz Photo

Hal Dietz, M.D.

Blade’s Founder

Oliver Eickelberg Photo

Oliver Eickelberg, M.D.

Scientific Advisor

Scott Friedman Photo

Scott Friedman, M.D.

Scientific Advisor

peter hirth Photo

Peter Hirth, Ph.D.

Scientific Advisor

Richard Hynes Photo

Richard Hynes, Ph.D.

Scientific Advisor

Mervyn Turner Photo

Mervyn Turner

Scientific Advisor

In Memoriam

John Nicholas image

John Nicholas, Ph.D

Vice President, Data Science

andrew tager image

Andrew Tager, M.D.

Scientific Advisor

Investors

mpm logo

deerfield logo

Osage University Partners logo

bristol myers squibb logo

novartis logo

pfizer ventures logo

One Ventures logo

Partners

Blade is actively seeking to in-license clinical or pre-clinical assets to expand our pipeline of products to treat fibrosis.

We are seeking to evaluate opportunities that represent a wide variety of molecular targets.

Parties developing products or technologies for fibrotic diseases that are interested in collaborating with Blade should contact our business development team. Contact: bd@blademed.com

Blade has partnered with the Scleroderma Research Foundation (SRF) to treat disorders of fibrosis, including scleroderma. Our founder, Hal Dietz, M.D., has been working closely with SRF for several years, and Blade has provided support through its research grant program.